Marengo Therapeutics Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Invikafusp alfa (STAR0602) and Trodelvy® in both Metastatic TNBC and Metastatic HR+/HER2- Breast Cancers

Excerpt from the Press Release:

• Invikafusp alfa has recently demonstrated single agent clinical activity across different PD-1 resistant cancers in the ongoing START-001 Phase1/2 clinical study
• The collaboration plans to evaluate the combination of Marengo’s first-in-class TCR Vβ selective dual T cell agonist, STAR0602 (Invikafusp alfa), with Trodelvy (sacituzumab govitecan-hziy) Gilead’s Trop-2 directed ADC in a new multi-center Phase I/II clinical study (START-002)
• Marengo will sponsor the clinical trial and Gilead will provide Trodelvy

CAMBRIDGE, Mass., Sept. 13, 2024 /PRNewswire/ — Marengo Therapeutics, Inc., a clinical-stage biotech company pioneering a new way to activate T cells targeting the Vβ chain of the T cell receptor to select the optimal T cell subsets against cancer, today announced that it has entered into a clinical study collaboration and supply agreement with Gilead Sciences, Inc. to study the combination of STAR0602 (Invikafusp alfa) with Trodelvy^® (sacituzumab govitecan-hziy), a Trop-2-directed antibody-drug conjugate (ADC), as a potential treatment for adult patients with metastatic hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer and metastatic triple-negative breast cancer (TNBC).

The planned combination trial, sponsored by Marengo, is expected to commence soon. This study will evaluate the safety, tolerability, and preliminary efficacy of STAR0602 (Invikafusp alfa) in combination with Trodelvy in patients with metastatic TNBC or metastatic HR+/HER2- breast cancer, aiming to explore a novel therapeutic strategy that could offer new treatment options for patients.

“We are excited about the clinical potential of combining our novel selective dual T cell activator with Gilead’s antibody-drug conjugate, Trodelvy,” said Kevin Chin, M.D., Chief Medical Officer of Marengo Therapeutics. “This innovative approach leverages the strengths of two unique modalities to target and potentially eradicate cancer cells more effectively. With the possibility to deliver target cytotoxic agents directly to tumors, which release more tumor antigens for selectively activated and expanded Vβ6/10 T cells to recognize and build long-term immune memory, we believe this combination may have the potential to improve cancer patient outcomes.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release